Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis
Wiendl H, Airas L, Chitnis T, Williams M, Nakahara J, Bermel R, Loop B, Hayek G, Bhatt A, Hunter B, Zhang Y, Karan R, Willi R, Kieseier B, Montalban X. Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2023, 80: 105315. DOI: 10.1016/j.msard.2023.105315.Peer-Reviewed Original ResearchBruton's tyrosine kinaseDisease activitySerum neurofilament light chain concentrationNeurofilament light chain concentrationOpen-label extensionKey secondary endpointDisability Status ScaleNew oral treatmentRecent disease activityLight chain concentrationsPercentage of participantsCovalent BTK inhibitorImmune regulatory networkRelated neuroinflammationDisability progressionPrimary endpointSecondary endpointsT1 lesionsTyrosine kinaseOral treatmentRelapse rateT2 lesionsMulticenter studyMultiple sclerosisSafety profile
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply